NEWSROOM
Product updates, regulatory analysis, and announcements from QMB and QualiVerse®, written for teams navigating FDA clearance.
Latest insights
Before an investor schedules a call, your digital presence, regulatory posture, and clinical data have already shaped their impression. Here is what sophisticated investors evaluate.
Regulatory delay in MedTech is not just lost time. It burns capital, weakens market position, and raises investor risk. Here is how to quantify the cost before you are living it.
Most medical device companies take the 510(k) route, and eSTAR is now the required submission template. Here is what MedTech teams need in place before they open it.
In MedTech, an unexplained answer is a dangerous one. QualiVerse® uses Explainable AI to ensure every compliance output is backed by clear, human-readable logic.
AI coding tools are changing how MedTech teams build. But building faster and clearing faster are two different things. Here is what founders need to understand before they confuse one for the other.
Stay in the loop
Subscribe for regulatory analysis, product updates, and announcements from QMB, delivered to your inbox.
Move at the Speed of Innovation
See QualiVerse® in Action